rac-N-(1-(5-isopropyl-1H-pyrazole-3-carbonyl)pyrrolidin-3-yl)cyclobutanecarboxamide

ID: ALA4059597

Chembl Id: CHEMBL4059597

PubChem CID: 121279737

Max Phase: Preclinical

Molecular Formula: C16H24N4O2

Molecular Weight: 304.39

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  CC(C)c1cc(C(=O)N2CCC(NC(=O)C3CCC3)C2)n[nH]1

Standard InChI:  InChI=1S/C16H24N4O2/c1-10(2)13-8-14(19-18-13)16(22)20-7-6-12(9-20)17-15(21)11-4-3-5-11/h8,10-12H,3-7,9H2,1-2H3,(H,17,21)(H,18,19)

Standard InChI Key:  WFZQSICPYNAMNU-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA4059597

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 304.39

Molecular Weight (Monoisotopic): 304.1899

AlogP: 1.66

#Rotatable Bonds: 4

Polar Surface Area: 78.09

Molecular Species: NEUTRAL

HBA: 3

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 11.12

CX Basic pKa: 1.00

CX LogP: 1.24

CX LogD: 1.24

Aromatic Rings: 1

Heavy Atoms: 22

QED Weighted: 0.89

Np Likeness Score: -2.20

References

1. Liang J, Labadie S, Zhang B, Ortwine DF, Patel S, Vinogradova M, Kiefer JR, Mauer T, Gehling VS, Harmange JC, Cummings R, Lai T, Liao J, Zheng X, Liu Y, Gustafson A, Van der Porten E, Mao W, Liederer BM, Deshmukh G, An L, Ran Y, Classon M, Trojer P, Dragovich PS, Murray L..  (2017)  From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors.,  27  (13): [PMID:28512031] [10.1016/j.bmcl.2017.05.016]

2. Liang J, Labadie S, Zhang B, Ortwine DF, Patel S, Vinogradova M, Kiefer JR, Mauer T, Gehling VS, Harmange JC, Cummings R, Lai T, Liao J, Zheng X, Liu Y, Gustafson A, Van der Porten E, Mao W, Liederer BM, Deshmukh G, An L, Ran Y, Classon M, Trojer P, Dragovich PS, Murray L..  (2017)  From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors.,  27  (13): [PMID:28512031] [10.1016/j.bmcl.2017.05.016]

3. Liang J, Labadie S, Zhang B, Ortwine DF, Patel S, Vinogradova M, Kiefer JR, Mauer T, Gehling VS, Harmange JC, Cummings R, Lai T, Liao J, Zheng X, Liu Y, Gustafson A, Van der Porten E, Mao W, Liederer BM, Deshmukh G, An L, Ran Y, Classon M, Trojer P, Dragovich PS, Murray L..  (2017)  From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors.,  27  (13): [PMID:28512031] [10.1016/j.bmcl.2017.05.016]

4. Yang GJ, Wu J, Miao L, Zhu MH, Zhou QJ, Lu XJ, Lu JF, Leung CH, Ma DL, Chen J..  (2021)  Pharmacological inhibition of KDM5A for cancer treatment.,  226  [PMID:34555614] [10.1016/j.ejmech.2021.113855]

Source

Source(1):

• Scientific Literature